WO2009140624A3 - Activateurs de la glucokinase - Google Patents

Activateurs de la glucokinase Download PDF

Info

Publication number
WO2009140624A3
WO2009140624A3 PCT/US2009/044190 US2009044190W WO2009140624A3 WO 2009140624 A3 WO2009140624 A3 WO 2009140624A3 US 2009044190 W US2009044190 W US 2009044190W WO 2009140624 A3 WO2009140624 A3 WO 2009140624A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
glucokinase activators
methods
glucokinase
str
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044190
Other languages
English (en)
Other versions
WO2009140624A2 (fr
Inventor
Zacharia Cheruvallath
Stephen L. Gwaltney
Andrew John Jennings
Mark Sabat
Jeffrey A Stafford
Mingnam Tang
Haxia Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda California Inc
Original Assignee
Takeda San Diego Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41076813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009140624(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2011509762A priority Critical patent/JP5513492B2/ja
Priority to MX2010012298A priority patent/MX2010012298A/es
Priority to CA 2724116 priority patent/CA2724116A1/fr
Priority to CN2009801273588A priority patent/CN102105451B/zh
Priority to AU2009246167A priority patent/AU2009246167B2/en
Priority to EP09747705.3A priority patent/EP2294053B1/fr
Priority to GEAP2009012029 priority patent/GEP20135783B/en
Priority to NZ589084A priority patent/NZ589084A/en
Application filed by Takeda San Diego Inc filed Critical Takeda San Diego Inc
Priority to UAA201015121A priority patent/UA103895C2/ru
Priority to EA201071320A priority patent/EA018988B1/ru
Priority to BRPI0912802A priority patent/BRPI0912802A2/pt
Publication of WO2009140624A2 publication Critical patent/WO2009140624A2/fr
Publication of WO2009140624A3 publication Critical patent/WO2009140624A3/fr
Priority to IL209062A priority patent/IL209062A/en
Priority to ZA2010/07975A priority patent/ZA201007975B/en
Priority to TNP2010000527A priority patent/TN2010000527A1/fr
Anticipated expiration legal-status Critical
Priority to MA33420A priority patent/MA32391B1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention porte sur des composés destinés à être utilisés avec la glucokinase, lesquels composés répondent à la formule: ##STR##, dans laquelle les variables sont telles que définies dans la description. L'invention se rapporte également à des compositions pharmaceutiques, des trousses et des articles manufacturés renfermant lesdits composés. L'invention concerne aussi des procédés de fabrication des composés, des intermédiaires utilisés dans leur fabrication et des procédés d'utilisation des composés.
PCT/US2009/044190 2008-05-16 2009-05-15 Activateurs de la glucokinase Ceased WO2009140624A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EA201071320A EA018988B1 (ru) 2008-05-16 2009-05-15 Активаторы глюкокиназы
MX2010012298A MX2010012298A (es) 2008-05-16 2009-05-15 Activadores de glucocinasa.
CA 2724116 CA2724116A1 (fr) 2008-05-16 2009-05-15 Activateurs de la glucokinase
CN2009801273588A CN102105451B (zh) 2008-05-16 2009-05-15 葡糖激酶活化剂
AU2009246167A AU2009246167B2 (en) 2008-05-16 2009-05-15 Glucokinase activators
EP09747705.3A EP2294053B1 (fr) 2008-05-16 2009-05-15 Activateurs de la glucokinase
GEAP2009012029 GEP20135783B (en) 2008-05-16 2009-05-15 Glucokinase activators
NZ589084A NZ589084A (en) 2008-05-16 2009-05-15 Glucokinase activators
UAA201015121A UA103895C2 (ru) 2008-05-16 2009-05-15 Активаторы глюкокиназы
JP2011509762A JP5513492B2 (ja) 2008-05-16 2009-05-15 グルコキナーゼ活性剤
BRPI0912802A BRPI0912802A2 (pt) 2008-05-16 2009-05-15 ativadores de glicoquinase
IL209062A IL209062A (en) 2008-05-16 2010-11-01 Annotations 2– (h1– pyrazole – 1 – yl) –3– (tetrahydro– h2– pyran – 4 – yl) propanamide Optional supplements with benzene and pyridine and their pharmaceutical preparations
ZA2010/07975A ZA201007975B (en) 2008-05-16 2010-11-08 Glucokinase activators
TNP2010000527A TN2010000527A1 (en) 2009-05-15 2010-11-12 Glucokinase activators
MA33420A MA32391B1 (fr) 2008-05-16 2010-12-10 Activateurs de la glucokinase

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5405208P 2008-05-16 2008-05-16
US61/054,052 2008-05-16
US10837008P 2008-10-24 2008-10-24
US61/108,370 2008-10-24

Publications (2)

Publication Number Publication Date
WO2009140624A2 WO2009140624A2 (fr) 2009-11-19
WO2009140624A3 true WO2009140624A3 (fr) 2010-05-27

Family

ID=41076813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044190 Ceased WO2009140624A2 (fr) 2008-05-16 2009-05-15 Activateurs de la glucokinase

Country Status (27)

Country Link
US (4) US8563730B2 (fr)
EP (1) EP2294053B1 (fr)
JP (1) JP5513492B2 (fr)
KR (1) KR20110018366A (fr)
CN (1) CN102105451B (fr)
AR (1) AR071811A1 (fr)
AU (1) AU2009246167B2 (fr)
BR (1) BRPI0912802A2 (fr)
CA (1) CA2724116A1 (fr)
CL (1) CL2009001203A1 (fr)
CO (1) CO6321274A2 (fr)
CR (1) CR11827A (fr)
DO (1) DOP2010000351A (fr)
EA (1) EA018988B1 (fr)
EC (1) ECSP10010688A (fr)
GE (1) GEP20135783B (fr)
IL (1) IL209062A (fr)
MA (1) MA32391B1 (fr)
MX (1) MX2010012298A (fr)
MY (1) MY152749A (fr)
NZ (1) NZ589084A (fr)
PE (2) PE20141375A1 (fr)
SG (1) SG190625A1 (fr)
TW (1) TWI445707B (fr)
UY (1) UY31830A (fr)
WO (1) WO2009140624A2 (fr)
ZA (1) ZA201007975B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642597B2 (en) * 2007-08-27 2014-02-04 Basf Se Pyrazole compounds for controlling invertebrate pests
US20100330177A1 (en) * 2008-02-05 2010-12-30 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
BRPI0912802A2 (pt) 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
RS52872B (sr) 2008-08-27 2013-12-31 Takeda Pharmaceutical Company Limited Jedinjenja pirola
KR101258331B1 (ko) * 2008-09-11 2013-04-26 화이자 인코포레이티드 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도
PL2342196T3 (pl) * 2008-09-24 2015-12-31 Basf Se Związki pirazolowe do zwalczania szkodników będących bezkręgowcami
WO2011003796A1 (fr) 2009-07-06 2011-01-13 Basf Se Composés pyridazine destinés à la lutte contre les nuisibles invertébrés
WO2011003793A1 (fr) 2009-07-06 2011-01-13 Basf Se Composés pyridazine destinés à la lutte contre les nuisibles invertébrés
WO2011009804A2 (fr) 2009-07-24 2011-01-27 Basf Se Composés dérivés de pyridine pour la lutte contre des animaux nuisibles invertébrés
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
CA2800498C (fr) 2010-03-31 2021-11-16 The Scripps Research Institute Nouvelle programmation de cellules
PT2576524T (pt) * 2010-05-26 2017-11-17 Vtv Therapeutics Llc Resumo
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP2013544787A (ja) * 2010-10-13 2013-12-19 タケダ カリフォルニア インコーポレイテッド アザインダゾール誘導体の調製方法
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
HK1202458A1 (en) 2012-05-17 2015-10-02 Vtv治疗有限责任公司 Glucokinase activator compositions for the treatment of diabetes
HK1213780A1 (zh) * 2013-03-04 2016-07-15 Vtv治疗有限责任公司 穩定的葡萄糖激酶活化劑組合物
EP2878339A1 (fr) 2013-12-02 2015-06-03 Siena Biotech S.p.A. Antagonistes SIP3
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
EP3372585B1 (fr) * 2014-12-19 2022-03-30 Aragon Pharmaceuticals, Inc. Procédé de préparation d'un composé de diarylthiohydantoïne
CN105092770B (zh) * 2015-01-12 2017-03-29 上海中医药大学 一种筛选二肽基肽酶四抑制剂的方法
WO2016202688A1 (fr) 2015-06-15 2016-12-22 Bayer Cropscience Aktiengesellschaft Phénoxyphénylamidines à substitution halogène et utilisation de celles-ci en tant que fongicides
MX2017016363A (es) 2015-06-15 2018-03-02 Bayer Cropscience Ag Fenoxifenilamidinas sustituidas con halogeno y el uso de estas como fungicidas.
EP3335559A1 (fr) 2016-12-14 2018-06-20 Bayer CropScience Aktiengesellschaft Combinaisons de composés actifs
WO2018109002A1 (fr) 2016-12-14 2018-06-21 Bayer Cropscience Aktiengesellschaft Combinaisons de composés actifs
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
SG11202011883RA (en) * 2018-05-31 2020-12-30 Hua Medicine Shanghai Ltd Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
US12391658B2 (en) 2020-02-18 2025-08-19 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
CA3181722A1 (fr) 2020-06-08 2021-12-16 Jing TENG Sels ou co-cristaux de {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acide acetique et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143434A2 (fr) * 2006-05-31 2007-12-13 Takeda San Diego, Inc. Activateurs de glucokinase

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9315846D0 (en) 1993-07-30 1993-09-15 Isis Innovation Tumour inhibitors
US5795726A (en) 1996-11-12 1998-08-18 Millennium Pharmaceuticals, Inc. Methods for identifying compounds useful in treating type II diabetes
GB9806692D0 (en) * 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
SI1169312T1 (en) 1999-03-29 2005-02-28 F. Hoffmann-La Roche Ag Glucokinase activators
US20030013633A1 (en) * 1999-06-07 2003-01-16 Rima Kaddurah-Daouk Use of molecules that modulate an energy related associated state
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
CA2393083C (fr) 1999-12-23 2010-01-26 Novartis Ag Utilisation d'agent hypoglycemique pour traiter un metabolisme du glucose defaillant
AU2001252270B2 (en) 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
KR100519826B1 (ko) 2000-05-08 2005-10-06 에프. 호프만-라 로슈 아게 파라-아민 치환된 페닐아미드 글루코키나제 활성화제
MXPA03000365A (es) 2000-07-20 2003-05-27 Hoffmann La Roche Bencenacetamida substituida con alfa-acilo y alfa-heteroatomo como activadores de la glucocinasa.
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
WO2003002062A2 (fr) 2001-06-29 2003-01-09 Tularik Inc. Derives de bis-aryl thiazole
AU2002349299A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
WO2003055482A1 (fr) 2001-12-21 2003-07-10 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
WO2003080585A1 (fr) 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide
WO2004026226A2 (fr) 2002-05-10 2004-04-01 Cytokinetics, Inc. Composes, compositions et procedes
BR0312023A (pt) 2002-06-27 2005-03-22 Novo Nordisk As Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica
GB0216097D0 (en) 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
US20040156826A1 (en) 2002-09-27 2004-08-12 Fernando Dangond Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
RU2309956C2 (ru) * 2002-10-03 2007-11-10 Ф.Хоффманн-Ля Рош Аг Производные индол-3-карбоксамида в качестве активаторов глюкокиназы
EP1556088A2 (fr) 2002-10-29 2005-07-27 Engene, Inc. Traitement de cancer par des modulations metaboliques
DE60336850D1 (en) 2003-01-06 2011-06-01 Lilly Co Eli Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
WO2004072066A1 (fr) 2003-02-11 2004-08-26 Prosidion Limited Composes d'amide a substitution tri(cyclo), activateurs de la glucokinase
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7179613B2 (en) * 2003-05-05 2007-02-20 Vanderbilt University Methods of screening for a candidate modulator of glucokinase
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
EP1532980A1 (fr) 2003-11-24 2005-05-25 Novo Nordisk A/S Carboxamides d'indole n-heteroarylé et leurs analogues, utiles comme des activateurs de glucokinase pour le traitement de diabetes
WO2005052132A2 (fr) 2003-11-24 2005-06-09 Exelixis, Inc Utilisation de modulateurs de la morphogenese de ramification comme genes modificateurs de la morphogenese de ramification et leurs procedes d'utilisation
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
US7750020B2 (en) 2004-04-02 2010-07-06 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes
CA2563192A1 (fr) 2004-04-21 2005-11-03 Prosidion Limited Composes amide tri(cyclo)-substitues
JP2008502658A (ja) 2004-06-17 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ 肝臓選択的グルコキナーゼ活性化因子の使用
WO2006002121A2 (fr) 2004-06-17 2006-01-05 Wisconsin Alumni Research Foundation Composes et procedes pour traiter des crises et des troubles paroxystiques
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
AU2005271016A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
WO2006024490A2 (fr) 2004-08-30 2006-03-09 Interstitial Therapeutics Methodes et compositions pour le traitement de la proliferation cellulaire
EP1891971A4 (fr) 2005-01-31 2010-02-03 Ajinomoto Kk Composition medicinale destinee a ameliorer ou a traiter l'intolerance au glucose, le pre-diabete, l'insulinoresistance et l'hyperinsulinemie et contenant un agent hypoglycemiant
JP2009501513A (ja) 2005-06-22 2009-01-22 メルク エンド カムパニー インコーポレーテッド Ｈｃｖ複製阻害の標的
US7565029B2 (en) * 2005-07-08 2009-07-21 Seiko Epson Corporation Method for determining camera position from two-dimensional images that form a panorama
WO2007007886A1 (fr) 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation Derive d'oxime et ses preparations
CA2621227A1 (fr) 2005-08-31 2007-03-08 Astellas Pharma Inc. Derive de thiazole
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
WO2007051846A1 (fr) * 2005-11-03 2007-05-10 Prosidion Ltd Amides a substitution tricyclo
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
JP2009515997A (ja) * 2005-11-18 2009-04-16 タケダ サン ディエゴ インコーポレイテッド グルコキナーゼ活性剤
JP2009520825A (ja) * 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
US8034822B2 (en) * 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
WO2007115968A2 (fr) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Procédé de préparation d'un activateur de glucokinase
JP5190448B2 (ja) 2006-04-20 2013-04-24 ファイザー・プロダクツ・インク グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物
US7842713B2 (en) * 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
US8163779B2 (en) * 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
WO2008084043A1 (fr) 2007-01-09 2008-07-17 Novo Nordisk A/S Activateurs de la glucokinase à base d'urée
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US20100183514A1 (en) 2007-05-29 2010-07-22 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2009022179A2 (fr) 2007-08-14 2009-02-19 Astrazeneca Ab Procédé
BRPI0912802A2 (pt) 2008-05-16 2015-10-13 Takeda San Diego Inc ativadores de glicoquinase
JP2013522294A (ja) 2010-03-18 2013-06-13 タケダ カリフォルニア インコーポレイテッド ２−アミノ−５−フルオロチアゾールの製造プロセス
JP2013544787A (ja) 2010-10-13 2013-12-19 タケダ カリフォルニア インコーポレイテッド アザインダゾール誘導体の調製方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143434A2 (fr) * 2006-05-31 2007-12-13 Takeda San Diego, Inc. Activateurs de glucokinase

Also Published As

Publication number Publication date
PE20141375A1 (es) 2014-10-23
US8563730B2 (en) 2013-10-22
EP2294053B1 (fr) 2016-01-06
JP2011520915A (ja) 2011-07-21
GEP20135783B (en) 2013-03-11
ECSP10010688A (es) 2011-04-29
DOP2010000351A (es) 2011-02-15
BRPI0912802A2 (pt) 2015-10-13
CL2009001203A1 (es) 2009-10-23
CO6321274A2 (es) 2011-09-20
IL209062A0 (en) 2011-01-31
TWI445707B (zh) 2014-07-21
AR071811A1 (es) 2010-07-14
CN102105451A (zh) 2011-06-22
CR11827A (es) 2011-03-09
AU2009246167B2 (en) 2013-08-22
EA018988B1 (ru) 2013-12-30
US20160009735A1 (en) 2016-01-14
CN102105451B (zh) 2013-11-13
CA2724116A1 (fr) 2009-11-19
US9139598B2 (en) 2015-09-22
KR20110018366A (ko) 2011-02-23
WO2009140624A2 (fr) 2009-11-19
MY152749A (en) 2014-11-28
JP5513492B2 (ja) 2014-06-04
MA32391B1 (fr) 2011-06-01
US20090286800A1 (en) 2009-11-19
UY31830A (es) 2010-01-05
EA201071320A1 (ru) 2011-06-30
SG190625A1 (en) 2013-06-28
PE20091901A1 (es) 2010-01-06
ZA201007975B (en) 2012-02-29
TW200948809A (en) 2009-12-01
MX2010012298A (es) 2011-03-15
AU2009246167A1 (en) 2009-11-19
AU2009246167A2 (en) 2010-12-16
US20120225887A1 (en) 2012-09-06
NZ589084A (en) 2012-06-29
IL209062A (en) 2015-08-31
US20140045859A1 (en) 2014-02-13
EP2294053A2 (fr) 2011-03-16

Similar Documents

Publication Publication Date Title
WO2009140624A3 (fr) Activateurs de la glucokinase
WO2007104034A3 (fr) Activateurs de la glucokinase
WO2008079787A8 (fr) Activateurs de glucokinase
WO2008116107A3 (fr) Activateurs de glucokinase
MY150542A (en) Cmet inhibitors
WO2010111626A3 (fr) Inhibiteurs de la poly(adp-ribose)polymérase (parp)
WO2009146034A3 (fr) Inhibiteurs de kinases mapk/erk et procédés d’utilisation de ceux-ci
WO2007143434A3 (fr) Activateurs de glucokinase
MY152283A (en) Polo-like kinase inhibitirs
WO2007117995A3 (fr) Inhibiteurs de kinase
MY150596A (en) Hsp90 inhibitors
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
WO2008115890A3 (fr) Inhibiteurs de mapk/erk kinase
WO2009156462A3 (fr) Composés organiques
WO2009092752A3 (fr) Polyoléfines à éléments structuraux isotactiques, procédé de production desdites polyoléfines et leur utilisation
JO2985B1 (ar) مثبطات كينازmapk/erk
WO2010077740A3 (fr) Nouveaux composés antiviraux, compositions et procédés d'utilisation
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
WO2010102778A3 (fr) 3-aminoisoxazolopyridines substituées en tant que modulateurs de kcnq 2/3
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2008053334A3 (fr) Procédé amélioré de préparation de rosuvastatine calcique
WO2008054956A3 (fr) Inhibiteurs de kinases
WO2010011834A3 (fr) Sunitinib et ses sels et leurs polymorphes
WO2009129401A8 (fr) Inhibiteurs de kinases
WO2008075205A3 (fr) Procédé amélioré de préparation de la voriconazole

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980127358.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09747705

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 589084

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1001177

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2724116

Country of ref document: CA

Ref document number: MX/A/2010/012298

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009246167

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2010111929

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 12010502573

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2011509762

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10154094

Country of ref document: CO

Ref document number: 201011827

Country of ref document: CR

Ref document number: CR2010-011827

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2009246167

Country of ref document: AU

Date of ref document: 20090515

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009747705

Country of ref document: EP

Ref document number: DZP2010000762

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 8063/CHENP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12029

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 20107028256

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201071320

Country of ref document: EA

ENP Entry into the national phase

Ref document number: PI0912802

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101116